Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4D-310 in Adults With Fabry Disease and Cardiac Involvement
NCT05629559Phase 2Recruiting
- Sponsor
- 4D Molecular Therapeutics
- Start
- Oct 2022
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 2
01
Overview
A Phase 2 trial of 4D-310 in Fabry disease (FD), sponsored by 4D Molecular Therapeutics. Started Oct 2022; status: recruiting.
02
Drugs
4D-310
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT05629559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05629559.